Literature DB >> 12432165

Acute effects of Advance: a potential reduced exposure product for smokers.

A B Breland1, S E Evans, A R Buchhalter, T Eissenberg.   

Abstract

OBJECTIVE: To examine the acute effects of Advance, a potential reduced exposure product (PREP) for smokers marketed as a means to reduce exposure to toxic gases and tobacco specific nitrosamines. DESIGN, SETTING, PARTICIPANTS: Latin square ordered, three condition, laboratory based, crossover design with 20 smokers of light or ultra-light cigarettes (15 or more cigarettes/day). In each 2.5 hour condition, participants completed an 8-puff smoking bout from their own brand, Advance, or an unlit cigarette (that is, sham smoking) every 30 minutes for a total of four bouts. MAIN OUTCOME MEASURES: Subject rated measures of tobacco/nicotine withdrawal; carbon monoxide (CO), and heart rate; plasma nicotine concentrations.
RESULTS: Relative to own brand, Advance produced similar withdrawal suppression and heart rate increase, lower CO boost, and higher plasma nicotine concentrations.
CONCLUSIONS: PREPs for smokers need to be evaluated using a comprehensive strategy that includes empirical examination of acute and long term effects. Adequate withdrawal suppression and potentially lower concentrations of CO associated with Advance use are positive factors, although higher nicotine concentrations do not constitute "reduced exposure". Overall, longer exposure periods are necessary to determine carcinogen delivery. PREP evaluation is complex and should be completed objectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432165      PMCID: PMC1747694          DOI: 10.1136/tc.11.4.376

Source DB:  PubMed          Journal:  Tob Control        ISSN: 0964-4563            Impact factor:   7.552


  14 in total

1.  Waterpipe tobacco smoking and cigarette smoking: a direct comparison of toxicant exposure and subjective effects.

Authors:  Caroline O Cobb; Alan Shihadeh; Michael F Weaver; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2010-12-02       Impact factor: 4.244

2.  Preliminary investigation of the advertising and availability of PREPs, the new "safe" tobacco products.

Authors:  Norval Hickman; Elizabeth A Klonoff; Hope Landrine; Kennon Kashima; Bina Parekh; Senaida Fernandez; Kamala Thomas; Catherine Brouillard; Michele Zolezzi; Jennifer Jensen; Zorahna Weslowski
Journal:  J Behav Med       Date:  2004-08

3.  The time for tobacco industry sponsored PREP evaluation has arrived.

Authors:  T Eissenberg
Journal:  Tob Control       Date:  2006-02       Impact factor: 7.552

4.  Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology.

Authors:  Jennifer N Gray; Alison B Breland; Michael Weaver; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2008-09       Impact factor: 4.244

Review 5.  Nicotine and nonnicotine factors in cigarette addiction.

Authors:  Jed E Rose
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

Review 6.  Measures for assessing subjective effects of potential reduced-exposure products.

Authors:  Karen Hanson; Richard O'Connor; Dorothy Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 7.  Reconciling human smoking behavior and machine smoking patterns: implications for understanding smoking behavior and the impact on laboratory studies.

Authors:  Catalin Marian; Richard J O'Connor; Mirjana V Djordjevic; Vaughan W Rees; Dorothy K Hatsukami; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 8.  Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example.

Authors:  Richard J O'Connor; K Michael Cummings; Vaughan W Rees; Gregory N Connolly; Kaila J Norton; David Sweanor; Mark Parascandola; Dorothy K Hatsukami; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 9.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 10.  Clinical trials methods for evaluation of potential reduced exposure products.

Authors:  Dorothy K Hatsukami; Karen Hanson; Anna Briggs; Mark Parascandola; Jeanine M Genkinger; Richard O'Connor; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.